Phospho-BRCA2 (Ser3291) Antibody

Code CSB-PA079435
Size US$360
Order now
  • Western blot analysis of extracts from 293 cells using BRCA2 (Phospho-Ser3291) Antibody.The lane on the right is treated with the antigen-specific peptide.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) BRCA2 Polyclonal antibody
Uniprot No.
Target Names
Alternative Names
BRCA 2 antibody; BRCA1/BRCA2 containing complex subunit 2 antibody; Brca2 antibody; BRCA2; DNA repair associated antibody; BRCA2_HUMAN antibody; BRCC 2 antibody; BRCC2 antibody; Breast and ovarian cancer susceptibility gene early onset antibody; breast and ovarian cancer susceptibility protein 2 antibody; Breast cancer 2 early onset antibody; Breast Cancer 2 tumor suppressor antibody; Breast cancer susceptibility protein BRCA2 antibody; Breast cancer type 2 susceptibility protein antibody; BROVCA2 antibody; FACD antibody; FAD 1 antibody; FAD antibody; FAD1 antibody; FANCB antibody; FANCD 1 antibody; FANCD antibody; FANCD1 antibody; FANCD1 gene antibody; Fanconi anemia complementation group D1 antibody; Fanconi anemia group D1 protein antibody; GLM3 antibody; mutant BRCA2 antibody; OTTHUMP00000018803 antibody; OTTHUMP00000042401 antibody; PNCA2 antibody; XRCC11 antibody
Raised in
Species Reactivity
Peptide sequence around phosphorylation site of Serine 3291 (F-V-S(p)-P-A) derived from Human BRCA2.
Immunogen Species
Homo sapiens (Human)
Purification Method
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
It differs from different batches. Please contact us to confirm it.
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:1000
Troubleshooting and FAQs
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. Part of a PALB2-scaffolded HR complex containing RAD51C and which is thought to play a role in DNA repair by HR. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. May play a role in the extension step after strand invasion at replication-dependent DNA double-strand breaks; together with PALB2 is involved in both POLH localization at collapsed replication forks and DNA polymerization activity. In concert with NPM1, regulates centrosome duplication. Interacts with the TREX-2 complex (transcription and export complex 2) subunits PCID2 and SEM1, and is required to prevent R-loop-associated DNA damage and thus transcription-associated genomic instability. Silencing of BRCA2 promotes R-loop accumulation at actively transcribed genes in replicating and non-replicating cells, suggesting that BRCA2 mediates the control of R-loop associated genomic instability, independently of its known role in homologous recombination.
Gene References into Functions
  1. Evidence has been provided that the majority of the Cas9-induced single nicks at the target DNA strand rely on RAD51 and BRCA2 for efficient and scar-less DNA repair. PMID: 28067217
  2. It has been shown that BRCA2-mutant prostate cancer cells harbor increased genomic instability and a mutational profile that more closely resembles metastatic than localized disease. PMID: 28067867
  3. Germline mutations involving the Fanconi anemia pathway, such as BRCA2 are often implicated in Invasive Pancreatic Ductal Adenocarcinoma. PMID: 28870368
  4. The authors propose that BRCA2 antagonizes 53BP1, RIF1, and Artemis-dependent c-nonhomologous end-joining and alt-nonhomologous end-joining to prevent gross genomic instability in a RAD51-independent manner. PMID: 29133916
  5. region in the N terminus exhibits DNA binding activity and promotes RAD51-mediated homologous recombination PMID: 27628236
  6. BRCA2 germ line mutation is associated with unilateral triple-negative breast cancer. PMID: 29514593
  7. BRCA2 germ line mutation is associated with ovarian cancer. PMID: 29506471
  8. BRCA1/2 mutations are not uncommon among selected Jordanian females with breast cancer. PMID: 29409476
  9. male BRCA1/2 mutation carriers with breast and prostate cancer demonstrated a favorable 5-year survival. PMID: 29433453
  10. BRCA2 SNP is associated with Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas. PMID: 29298688
  11. this study identifies the importance of TDP1 as a novel determinant of response to CNDAC across various cancer types (especially non-small cell lung cancers), and demonstrates the differential involvement of BRCA2, PARP1, and TDP1 in the cellular responses to CNDAC, AraC, and CPT PMID: 28802254
  12. No evidence for a an association between the genotype at BRCA2 c.6937 + 594T>G and breast cancer risk. PMID: 29356578
  13. the physiological significance of GIPC3 as a genetic interactor of BRCA2 is supported by the observation that Brca2-null embryos with Gipc3 overexpression are developmentally more advanced than their control littermates. Taken together, we have uncovered a novel role for GIPC3 as a BRCA2 genetic interactor. PMID: 29021281
  14. BRCA2 mutation carriers showed earlier onset age of breast tumor and higher risk of developing contra lateral breast cancer in women from Murcia (south-eastern Spain). PMID: 28477318
  15. Results, including a comprehensive co-segregation analysis, indicate that the novel duplication identified has a pathogenic role and would be considered a causing-disease variant in genetic and oncologic counseling. PMID: 28620890
  16. In our EOBC cohort, a contralateral breast cancer was diagnosed in ~60% of BRCA1/2 carriers, but only in 8% of non-carriers. These findings show that BRCA1/2 mutations overwhelmingly lead to a contralateral disease when breast cancer is diagnosed at early age. PMID: 27726213
  17. Results showed that BRCA2 is down-regulated in epithelial ovarian cancer by lncRNA RP11-552M11.4 which promotes cell proliferation, migration and invasion. PMID: 29478268
  18. BRCA2 and CHEK2 play an important role in the genetic susceptibility to urinary tract cancers. PMID: 27632928
  19. The present study shows that the G allele carriers of BRCA2 rs9534275 were associated with increased serum total cholesterol and ApoB levels in the coronary artery disease patients and increased risk of coronary artery disease and ischemic stroke. PMID: 28982360
  20. BRCA2 rs144848 polymorphism is associated with cancer. PMID: 28418854
  21. Tumours arising in BRCA2 mutation carriers showed significantly higher methylation of candidate genes, than those arising in non-BRCA2 familial MBCs (average AMI 23.6 vs 16.6, p = 0.01, 45% of genes hypermethylated vs 34%, p < 0.01). PMID: 28893223
  22. role of BRCA2 splicing for acquired chemo-resistance in BRCA2 mutation associated malignancy PMID: 28617445
  23. Results show frequent BRCA2, EGFR, and NTRK1/2/3 mutations in mismatch repair-deficient colorectal cancers , sugggesting personalized medicine strategies to treat the patients with advanced disease who may have no remaining treatment options. PMID: 28591715
  24. In this study, we evaluated this novel mechanism of drug resistance in newly diagnosed, early-stage BRCA1/2-mutant breast cancer patients who had a poor response to platinum-based neoadjuvant chemotherapy. PMID: 28087643
  25. IGH/MYC-positive Burkitt lymphoma/leukemia cells have decreased BRCA2 and are sensitive to PARP1 inhibition alone or in combination with other chemotherapies. This study postulates that IGH/MYC-induced BRCA2 deficiency may predispose Burkitt lymphoma cells to synthetic lethality triggered by PARP1 inhibitors. PMID: 28634224
  26. This meta-analysis showed that a BRCA2 mutation predicted poor survival outcomes in patients with prostate cancer, especially in those undergoing treatments with radiotherapy. Therefore, the use of BRCA2 mutation as a clinical prognostic factor could help stratify the high-risk patients and provide clinical strategies for more effective targeted treatments for patients with prostate cancer. PMID: 28410213
  27. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system was employed to target and correct a FANCD1 gene deletion. The study shows the ability to correct a patient mutation in primary FANCD1 cells in a precise manner. PMID: 28613254
  28. Data indicate that c.1310_1313delAAGA mutation of BRCA2 gene is recurrent with high frequency in patients from the North-East region of Morocco. PMID: 28577564
  29. Patients with BRCA2 mutation were almost 25 times more likely to have chronic pancreatitis-like changes compared with sex-matched controls. PMID: 28375947
  30. Prevalence of pathogenic and likely pathogenic variants in the hotspots regions of BRCA2 was 23 and 6.3 % respectively in this cohort PMID: 28039656
  31. We present two cases of black South African patients with FA diagnosed with biallelic BRCA2 mutations and discuss the phenotypic consequences and implications for them and their families PMID: 28185119
  32. High BRCA2 expression is associated with drug resistance in ovarian cancer. PMID: 26959114
  33. IMPACT data were consistent with increased risks of onset among BRCA1 and BRCA2 mutation carriers PMID: 27742670
  34. In the very high-risk Bladder Cancer patients , several genes had a higher frequency of mutations than reported in the The Cancer Genome Atlas database, including BRCA2 . Mutation associations with receipt of neoadjuvant chemotherapy, nodal involvement, metastatic disease development, and survival were analyzed. PMID: 27520487
  35. three patients had biallelic inactivation of BRCA2, a tumor suppressor gene critical for homologous DNA repair. two had germline BRCA2 mutations. The third patient had somatic BRCA2 homozygous copy loss. Biallelic BRCA2 inactivation in Metastatic Castration-resistant Prostate Cancer warrants further exploration as a predictive biomarker for sensitivity to platinum c PMID: 26724258
  36. The current model places BRCA2 as a central regulator of genome stability by repairing DNA double strand breaks and limiting replication stress. [review] PMID: 27530658
  37. Increasing evidence on the molecular role of the BRCA2 protein in the homologous recombination of DNA damages suggest that BRCA2-related PDAC are sensitive to agents causing DNA cross-linking damage, such as platinum salts, and treatments targeting rescue DNA repair pathways, such as poly(ADP-ribose) polymerase inhibitors that are currently under investigation.[ review] PMID: 27511924
  38. Data show that BRCA2 was required for HDAC2/3 association with acetylated BubR1 in nocodazole (Noc)-arrested cells. PMID: 28985013
  39. Data show that mammary epithelial cells are inviable upon BRCA2 loss, which leads to replication stress associated with under replication, causing mitotic abnormalities and G1 arrest. PMID: 28904335
  40. We demonstrated an association between six previously published single nucleotide polymorphisms (rs15869 [ BRCA2], rs1805389 [ LIG4], rs8079544 [ TP53], rs25489 [ XRCC1], rs1673041 [ POLD1], and rs11615 [ ERCC1]) and subsequent CNS tumors in survivors of childhood cancer treated by radiation therapy. PMID: 28976792
  41. Patients with Fanconi anemia have higher incidences of ectopic neurohypophysis, adenohypophysis hypoplasia, platybasia and other midline central nervous system skull base posterior fossa abnormalities than age- and sex-matched controls. Patients with posterior fossa abnormalities, including pontocerebellar hypoplasia, are more likely to have biallelic BRCA2 mutations. PMID: 28283722
  42. CDNA representing BRCA2 alternate splice sites was amplified. PMID: 27060066
  43. WTIP interacts with BRCA2 and might be responsible for BRCA2 centrosome localization in cervical cancer cell. PMID: 27535760
  44. Founder mutations in BRCA2 contribute to an increased risk of ovarian and breast cancer in the western Danish population. PMID: 26833046
  45. BRCA2 germline mutation is associated with triple-negative breast cancer. PMID: 27553291
  46. BRCA2 c.68-7T>A pathogenic mutation from Norwegian breast or ovarian cancer cohort PMID: 27495310
  47. Architectural plasticity of human BRCA2-RPA-RAD51 complexes in DNA break repair has been described. PMID: 28168276
  48. These findings suggest that R2787H variant of BRCA2 could have potential functional impact. PMID: 27211102
  49. Even if a BRCA2 mutation is already identified within a family, the presence of early onset breast cancer affected non-carriers hampers accurate risk estimates for both mutation carriers and other negative family members. PMID: 28199346
  50. This study detected monoallelic L1053X mutation causing the same stop codon in BRCA2 protein sequence at the same position in four Sudanese female breast cancer patients out of nine from different families. PMID: 28814288

Show More

Hide All

Involvement in disease
Breast cancer (BC); Pancreatic cancer 2 (PNCA2); Breast-ovarian cancer, familial, 2 (BROVCA2); Fanconi anemia complementation group D1 (FANCD1); Glioma 3 (GLM3)
Subcellular Location
Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.
Tissue Specificity
Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.
Database Links

HGNC: 1101

OMIM: 114480

KEGG: hsa:675

STRING: 9606.ENSP00000369497

UniGene: Hs.34012

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To